NGLFINE
NGL Fine-Chem Limited (NGLFINE) Stock Analysis
NGL Fine-Chem Limited is an Indian veterinary and animal health company manufacturing APIs and formulations for poultry and livestock globally. It exports active ingredients to regulated and semi-regulated markets. Animal protein demand and farm economics support volumes. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - General
₹3,041.30
+7.38% 1W | +105.70% 52W
Market Cap
1.9k CR
P/E Ratio
32.8
52W High
₹3602
52W Low
₹1271
Div. Yield
0.06%
Beta
0.9
50 DMA
₹2792.6
200 DMA
₹2669.5
Profit Margin
10.7%
Inst. Own.
0%
🛑 HIT RESISTANCE
🛑 HIT RESISTANCE
Fundamentals
Profit & Loss
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 80 | 88 | 100 | 91 | 93 | 89 | 95 | 104 | 120 | 128 | 149 | 139 | 159 |
| YoY Sales growth | +18% | +22% | +33% | +28% | +17% | +1% | -5% | +15% | +29% | +43% | +57% | +34% | +32% |
| Expenses | 66 | 74 | 84 | 81 | 82 | 84 | 89 | 93 | 103 | 105 | 128 | 116 | 131 |
| Operating Profit | 14 | 14 | 16 | 9 | 12 | 5 | 6 | 11 | 17 | 22 | 21 | 23 | 28 |
| OPM % | 17% | 16% | 16% | 10% | 12% | 6% | 7% | 11% | 14% | 18% | 14% | 17% | 18% |
| Other Income | 3 | 4 | 4 | 6 | 5 | -0 | -1 | 6 | 2 | 5 | 2 | 7 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 7 |
| Profit before tax | 14 | 14 | 16 | 12 | 13 | 1 | 1 | 12 | 13 | 21 | 18 | 24 | 22 |
| Tax % | 25% | 30% | 23% | 22% | 26% | -1% | 49% | 22% | 26% | 24% | 24% | 25% | 25% |
| Net Profit | 10 | 10 | 12 | 9 | 10 | 1 | 1 | 9 | 10 | 16 | 13 | 18 | 16 |
| EPS in Rs | 16.96 | 16.24 | 19.94 | 14.92 | 15.88 | 2.07 | 0.87 | 14.96 | 15.59 | 25.40 | 21.84 | 29.78 | 26.30 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 153 | 152 | 258 | 318 | 278 | 339 | 368 | 501 | 575 |
| Sales growth | -1% | +70% | +23% | -12% | +22% | +9% | +36% | +41% | |
| Expenses | 121 | 130 | 178 | 249 | 243 | 285 | 333 | 421 | 480 |
| Operating Profit | 32 | 22 | 80 | 68 | 35 | 54 | 35 | 80 | 95 |
| OPM % | 21% | 14% | 31% | 21% | 13% | 16% | 10% | 16% | 17% |
| Other Income | 4 | 1 | 8 | 11 | 6 | 14 | 8 | 8 | 16 |
| Interest | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 5 | 4 |
| Depreciation | 6 | 8 | 8 | 10 | 11 | 12 | 12 | 20 | 22 |
| Profit before tax | 28 | 12 | 78 | 67 | 27 | 54 | 28 | 63 | 85 |
| Tax % | 27% | 31% | 27% | 25% | 25% | 24% | 24% | 24% | |
| Net Profit | 20 | 8 | 57 | 50 | 20 | 41 | 21 | 48 | 64 |
| EPS in Rs | 32.58 | 13.50 | 91.81 | 80.77 | 33.18 | 66.88 | 34.19 | 77.91 | 103.32 |
| Dividend Payout % | 5% | 13% | 2% | 2% | 5% | 3% | 5% | 2% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 22.0% | 14.0% | – |
| Profit CAGR | 37.0% | -1.0% | – |
Shareholding Pattern
Promoters72.74%
Public27.26%
Promoters72.74%
Public27.26%
Promoters72.73%
FIIs0.03%
Public27.23%
Promoters72.49%
FIIs0.05%
DIIs0.02%
Public27.43%
Promoters72.49%
FIIs0.04%
Public27.46%
Promoters73.53%
Public26.47%
Promoters72.74%
FIIs0.10%
Public27.16%
Promoters72.74%
Public27.26%
Promoters72.73%
FIIs0.03%
Public27.23%
Promoters72.49%
FIIs0.04%
Public27.46%
NGLFINE
Holdings Analysis
Key strengths & risk signals
82
Overall
82
Fundamental
82
Technical
Risks (1)
NEGLIGIBLE DIVIDEND! 0.06% yield - little to no income.
Strengths (4)
UNDERVALUED! PEG of 1.00 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (2792.6) is above 200-day average (2669.5) - positive signal.
EXCELLENT YEAR! Stock gained 105.7% in the last year.
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 11,838 vs down days: 4,445. Ratio: 2.66x
Fundamental & Technical Analysis
82Overall
82Fundamental
82Technical
Fundamental Breakdown
Growth Quality
30/30
Revenue CAGR: 21.8% (EXCELLENT, 15/15). Profit CAGR: 32.9% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 10.7% profit margin - acceptable profitability.
PEG Valuation
10/10
UNDERVALUED! PEG of 1.00 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.06% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 26.46% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
10/10
BULLISH TREND! 50-day average (2792.6) is above 200-day average (2669.5) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (3041.3) is above both moving averages.
Trend Pattern
10/20
AT RESISTANCE! Stock is at key resistance level.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 105.7% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 11,838 vs down days: 4,445. Ratio: 2.66x
RSI
3/5
NEUTRAL! RSI at 57.3 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 75.9% of 52W range - positive territory.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - 7.4% (1 week), 6.1% (1 month), -11.9% (3 months).
Beta
4/5
BELOW MARKET! Beta of 0.90 - slightly less volatile than market.
NGLFINE
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-30 | Concall PDF | |
| Q2FY262025-11-20 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - General · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NGLFINE | ₹3,041.30 | 32.8 | 10.7% | 21.8% | 32.9% | +105.7% | 82 | HIT RESISTANCE | +100.0% | +36.3% | +33.6% | -6.7% |
| SAIPARENT | ₹496.90 | 88.1 | 3.7% | 57.9% | 48.3% | +24.7% | 68 | APPROACHING SUPPORT | +64.1% | -33.5% | +264.3% | +9.1% |
| KOPRAN | ₹289.10 | 35.5 | 5.0% | 7.0% | -16.0% | +84.3% | 66 | CONSOLIDATING UP | -144.3% | -34.5% | +79.2% | +37.2% |
| TTKHLTCARE | ₹938.50 | 4.7 | 30.1% | 5.9% | -53.2% | -15.8% | 58 | BREAKDOWN | – | +946.9% | – | -9.4% |
| SMSPHARMA | ₹508.10 | 40.2 | 12.0% | 19.3% | – | +80.3% | 73 | APPROACHING RESISTANCE | +57.7% | +90.9% | +30.4% | +52.7% |
| CORONA | ₹2,329.70 | 68.1 | 13.3% | 16.6% | 29.7% | +64.6% | 80 | BREAKOUT | +15.3% | +33.1% | +22.2% | +25.0% |
| SENORES | ₹1,174.60 | 38.6 | 18.6% | 159.1% | 139.2% | +48.0% | 72 | BREAKDOWN | +21.9% | +28.7% | +25.0% | +6.7% |
| SANOFI | ₹3,301.40 | 20.7 | 20.0% | -12.6% | -19.3% | -27.9% | 57 | BREAKOUT | – | +39.8% | – | +12.3% |
Data from TradeAlone · Updated daily
